Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept and IL-2 in ALS
NCT06307301Phase 1Completed
- Sponsor
- Houston Methodist Research Institute
- Start
- Oct 2021
- Primary completion
- Dec 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abatacept in amyotrophic lateral sclerosis (ALS), sponsored by Houston Methodist Research Institute. Primary endpoint: Adverse events and laboratory abnormalities at 24 months. Started Oct 2021; status: completed.
02
Drugs
abatacept
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06307301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06307301.